Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front
Incyte $INCY has swooped in and gained control of Calithera’s $CALA number #2 cancer drug with a $53 million cash payday.
The collaboration gives Incyte …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
